The overall objective of this project is to develop a novel targeted immunotherapy strategy based on the use of immunogenic antigens (RNA) isolated from GBM slow-cycling cells as activator of immune effectors in the context of adoptive cell therapy to prevent recurrence in GBM. The specific goals of the project will be to validate the pool of RNA used to prime dendritic cells and generate treatment resistant tumor cells that will be used to assess the antitumor effect of engineered T cell products.
